Tafenoquine: A 2018 Novel FDA-Approved Prodrug for the Radical Cure of Plasmodium vivax Malaria and Prophylaxis of Malaria

Tafenoquine (an 8-aminoquinoline) was approved by the Food and Drug Administration (FDA) in 2018 for the radical cure of Plasmodium vivax malaria and preventive action against malaria. Despite the fact that the mechanism of action of the drug remains unclear, all studies indicated that a metabolite...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayence, Annie, Vanden Eynde, Jean Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789594/
https://www.ncbi.nlm.nih.gov/pubmed/31366060
http://dx.doi.org/10.3390/ph12030115
_version_ 1783458654980145152
author Mayence, Annie
Vanden Eynde, Jean Jacques
author_facet Mayence, Annie
Vanden Eynde, Jean Jacques
author_sort Mayence, Annie
collection PubMed
description Tafenoquine (an 8-aminoquinoline) was approved by the Food and Drug Administration (FDA) in 2018 for the radical cure of Plasmodium vivax malaria and preventive action against malaria. Despite the fact that the mechanism of action of the drug remains unclear, all studies indicated that a metabolite is responsible for its efficacy. Routes for the preparation of the drug are described.
format Online
Article
Text
id pubmed-6789594
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67895942019-10-16 Tafenoquine: A 2018 Novel FDA-Approved Prodrug for the Radical Cure of Plasmodium vivax Malaria and Prophylaxis of Malaria Mayence, Annie Vanden Eynde, Jean Jacques Pharmaceuticals (Basel) Brief Report Tafenoquine (an 8-aminoquinoline) was approved by the Food and Drug Administration (FDA) in 2018 for the radical cure of Plasmodium vivax malaria and preventive action against malaria. Despite the fact that the mechanism of action of the drug remains unclear, all studies indicated that a metabolite is responsible for its efficacy. Routes for the preparation of the drug are described. MDPI 2019-07-30 /pmc/articles/PMC6789594/ /pubmed/31366060 http://dx.doi.org/10.3390/ph12030115 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Mayence, Annie
Vanden Eynde, Jean Jacques
Tafenoquine: A 2018 Novel FDA-Approved Prodrug for the Radical Cure of Plasmodium vivax Malaria and Prophylaxis of Malaria
title Tafenoquine: A 2018 Novel FDA-Approved Prodrug for the Radical Cure of Plasmodium vivax Malaria and Prophylaxis of Malaria
title_full Tafenoquine: A 2018 Novel FDA-Approved Prodrug for the Radical Cure of Plasmodium vivax Malaria and Prophylaxis of Malaria
title_fullStr Tafenoquine: A 2018 Novel FDA-Approved Prodrug for the Radical Cure of Plasmodium vivax Malaria and Prophylaxis of Malaria
title_full_unstemmed Tafenoquine: A 2018 Novel FDA-Approved Prodrug for the Radical Cure of Plasmodium vivax Malaria and Prophylaxis of Malaria
title_short Tafenoquine: A 2018 Novel FDA-Approved Prodrug for the Radical Cure of Plasmodium vivax Malaria and Prophylaxis of Malaria
title_sort tafenoquine: a 2018 novel fda-approved prodrug for the radical cure of plasmodium vivax malaria and prophylaxis of malaria
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789594/
https://www.ncbi.nlm.nih.gov/pubmed/31366060
http://dx.doi.org/10.3390/ph12030115
work_keys_str_mv AT mayenceannie tafenoquinea2018novelfdaapprovedprodrugfortheradicalcureofplasmodiumvivaxmalariaandprophylaxisofmalaria
AT vandeneyndejeanjacques tafenoquinea2018novelfdaapprovedprodrugfortheradicalcureofplasmodiumvivaxmalariaandprophylaxisofmalaria

Ejemplares similares